Aspira Women's Health Inc.
Close on Oct 19, 2026
- Market cap
- $9.91M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | $2.30M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 19, 2025 | Before market open | $2.28M | $-0.09 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | After market close | $2.30M | $-0.08 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | $2.30M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | $2.42M | $-0.28 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | $2.15M | $-0.39 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | $2.10M | $-0.30 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | After market close | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 22, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on Nov 14, 2024, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| operating cash utilization target | full year 2024 | $13.00M to $14.50M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Aspira Women's Health filed with the SEC
historical facts contained in this presentation, including statements regarding Aspira Women’s Health, Inc.’s (the “Company’s” or Aspira”)
Regulation FD disclosure · EX-99.1 to Form 8-K
Aspira Announces Third Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Women’s Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces Second Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Women’s Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women’s Health
Other events · EX-99.1 to Form 8-K
Announces First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
$2.0 Million Equity Purchase Agreement
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Women’s Health Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Women’s Health Announces Closing of
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Women’s Health Reports Selected Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
it was my honor to share news of an exciting development that we believe will shape Aspira Women’s Health for many years to come.
Other events · EX-99.1 to Form 8-K
Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Aspira Women’s Health Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Aspira Women’s Health Provides Commercial, Reimbursement and Cash Guidance Updates
Regulation FD disclosure · EX-99.1 to Form 8-K
Aspira Women’s Health Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
Regulation FD disclosure · EX-99.1 to Form 8-K
Aspira Women’s Health Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aspira Women’s Health Establishes a New Clinical Advisory Board
Other events · EX-99.1 to Form 8-K
Aspira Women’s Health ® Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K/A
First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year
Results of operations · EX-99.1 to Form 8-K
Aspira Women’s Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023
Results of operations · EX-99.1 to Form 8-K
Aspira Women’s Health Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K/A
Regulation FD disclosure · EX-99.1 to Form 8-K/A
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Achievement of Cash Utilization Guidance, and Other Highlights
Results of operations · EX-99.1 to Form 8-K
Aspira Women’s Health Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aspira Women’s Health Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aspira Women’s Health Inc. 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aspira Women’s Health Inc. 8-K
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY ASPIRA WOMEN'S HEALTH INC.
Regulation FD disclosure · EX-99.1 to Form 8-K
Aspira Women’s Health Announces Fourth Quarter Operational Metrics and Provides Updates on Its OvaWatch and EndoCheck Programs
Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K